Precinical proof-of-concept demonstration of the protective effect of the Administration for 36 days of IMA001 during an acute episode of vaso-occlusion in sickle Townes HbSS mice. IMA001 reduced intravascular hemolysis and inhibited microvascular stasis in animals subjected to an acute hypoxia followed by reoxygenation (8% oxygen for 3 hours and reoxygenation at room air for 1 hour).
Imalia Announces Completion of Clinical Phase of Indian Randomized Pilot Study on IMA001 in Sickle Cell Disease
Completion of the clinical phase of randomized, double blind, placebo controlled pilot study conducted